Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04858139
Other study ID # Swissmedic N°2020DR2163
Secondary ID 2019-00897
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 27, 2021
Est. completion date March 2024

Study information

Verified date August 2021
Source Centre Hospitalier Universitaire Vaudois
Contact Lorenz Hirt, MD
Phone +41213141268
Email Lorenz.Hirt@chuv.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this exploratory randomized double blind placebo controled trial, lactate solution or placebo will be administered to acute ischemic stroke patients selected for endovascular treatment (EVT) without intravenous thrombolysis. The treatment will be administered within one hour after EVT. Primary outcome measures will be lactate and metabolite concentrations in the ischemic lesion, in the penumbra and contralaterally, evaluated by magnetic resonance spectroscopy(MRS). Secondary outcome measures will be evolution of the ischemic penumbra, clinical outcome at 3 months.The trial will end when 10 patients per group have completed the study.


Description:

This is an exploratory randomized double blind placebo controled trial on acute ischemic stroke patients. Lactate solution or placebo will be administered to acute ischemic stroke patients selected for endovascular treatment (EVT) without intravenous thrombolysis. Magnetic resonance spectroscopy will be performed before EVT to measure metabolite concentrations in the ischemic core, penumbra and in the contralateral hemisphere. The treatment will be administered within one hour after EVT. As soon as the patient is stabilized, she/he will undergo an additional magnetic resonance imaging (MRI) with magnetic resonance spectroscopy (MRS). MRS will also be performed during the control MRI after 24 hours. Neurological deficits will be evaluated on admission, at 24 hours using the National Institute of Health Stroke Scale (NIHSS), and at 3 months, with both NIHSS and the modified Rankin scale. Primary outcome measures will be lactate and metabolite concentrations changes in the ischemic lesion, in the penumbra and the contralateral side, evaluated by magnetic resonance spectroscopy after intervention compared to baseline MRS values. Secondary outcome measures will be evolution of the ischemic penumbra and clinical outcome at 3 months. The trial will end when 10 patients per group have completed the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Acute ischemic stroke with arterial occlusion affecting middle cerebral artery (segment M1or segment 2) or internal carotid artery (T-type or L-type occlusion) selected for EVT - not eligible for intravenous thrombolysis (IVT) - Moderate to severe stroke (NIHSS > or = 4), and preadmission mRS > or = 3) - Perfusion - diffusion mismatch - Obtain consent from independent Doctor Randomisation criteria - If possible oral consent from patient or relatives - Treatment administration possible within 1h from EVT Exclusion Criteria: - Rapid neurological recovery - Clinically unstable patient - Contraindications to MRI - Blood Na+ > 155 mmol/l or plasma osmolality > 320 mosmol/l - Medical history of traumatic brain injury (TBI), neurodegenerative disease, intracranial hemorrhage, cerebral aneurysm, brain tumour - Medical history of psychiatric disorders - Liver insufficiency - Heart failure - Pregnancy (pregnancy test required in women aged under 50 unless patient or relatives indicate that the patient is not pregnant) - Participation in another clinical trial in the last 30 days - Lack of consent of an independent Doctor

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lactate
Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
Placebo
Intravenous injection (20 min)

Locations

Country Name City State
Switzerland CHUVaudois Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Vaudois

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Does the administered lactate reach the brain Measurement of lactate and other metabolites in lesion, penumbra, contralateral side using magnetic resonance spectroscopy measured after intervention and compared to baseline values.
After intervention, the MRS will be performed as soon as possible considering that these patients have an EVT under general anesthesia and need to be stabilised after the EVT and study treatment intervention before the MRS.
Measurement after intervention (as soon as the patient condition allows performing an MRI; estimated between 1 and 2 hours)
Primary Does the administered lactate persist in the brain at 24 hours Measurement of lactate and other metabolites in lesion, penumbra, contralateral side using magnetic resonance spectroscopy measured at 24 hours and compared to baseline values. The MRS will be performed during the routine clinical MRI approximately 24 hours after EVT
Secondary Effect of lactate on neuronal death after intervention Assessment of N-acetyl aspartate (NAA), a neuronal marker, using MRS and compared to baseline values, in the ischemic core and in the ischemic penumbra. Measurement after intervention (as soon as the patient condition allows performing an MRI; estimated between 1 and 2 hours)
Secondary Effect of lactate on neuronal death at 24 hours Assessment of N-acetyl aspartate (NAA), a neuronal marker, using MRS and compared to baseline values, in the ischemic core and in the ischemic penumbra. Measurement at during the routine control MRS, approximately 24 hours after EVT
Secondary Effect of lactate on evolution of lesion at 24 hours Assessment of lesion using diffusion weighted Imaging (DWI) compared to baseline value At 24 hours
Secondary Effect of lactate on evolution of penumbra at 24 hours Check impact of intervention on the penumbra using perfusion weighted imaging (PWI) at 24 hours compared to baseline This evaluation will be based on the routine MRI evaluation performed approximately 24 hours after EVT
Secondary Clinical outcome at 24 hours Evolution of the neurological score (NIHSS) and compared to baseline assessment at 24 hours
Secondary Clinical outcome at 3 months Evolution of neurological score (NIHSS) compared to baseline value Measurement at follow up (3 months)
Secondary Handicap at 3 months Evolution of neurological handicap (mRS) compared to baseline value Measurement at follow up (3 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients